NeueHealth — Q2 2024 Earnings Presentation
11 slides from NeueHealth's earnings presentation, Aug 7, 2024
Slide 1: NeueHealth Second Quarter 2024 - Earnings Presentation
NeueHealth Second Quarter 2024 - Earnings Presentation August 7, 2024 Privileged & Confidential | © 2024
Slide 2: Disclaimer
Disclaimer Statements made in this presentation that are not statements of historical fact, including statements about our beliefs and expectations, are forward-looking statements and should be evaluated as such. Forward-looking statements include information concerning possible or assumed future re
Slide 3: NeueHealth: A Value-Driven Healthcare Company
NeueHealth: A Value-Driven Healthcare Company A value-driven, consumer-centric care model grounded in strong, ongoing relationships with provider and payor partners and proactive consumer engagement NeueHealth Value-driven care delivery and provider enablement business partnering with leading health
Slide 4: Overview of Q2 2024 Results for Continuing Operations
Overview of Q2 2024 Results for Continuing Operations Continued Momentum in Q2 Driven by Solid Performance in NeueCare and NeueSolutions Segments Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Q2 ‘24 Revenue of $226.0 million is slig
Slide 5: Overview of Year-to-Date 2024 Results for Continuing Operations
Overview of Year-to-Date 2024 Results for Continuing Operations Strong Year-to-Date Results Reflect Focus on Driving Long-Term, Sustainable Growth of Value-Driven Model Enterprise Metrics ($M) Revenue Gross Margin Adj. Operating Cost Ratio(1) Adjusted EBITDA(2) Key Considerations • Revenue of $471.1
Slide 6: Balance Sheet and Liquidity Highlights
Balance Sheet and Liquidity Highlights Focused on building a strong foundation for long-term sustainable growth Summary Balance Sheet Q2 ‘24 Key Considerations June 30, December 31, • $277.8 million in total cash and investments, including $135.6 million ($ in thousands) 2024 2023 in regulated entit
Slide 7: Appendix
Appendix
Slide 8: Non-GAAP Reconciliation: Adjusted EBITDA
Non-GAAP Reconciliation: Adjusted EBITDA Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, ($ in thousands) 2024 2023 2024 2023 Net Loss $ (57,698) $ (88,627) $ (61,875) $ (258,088) Loss from discontinued operations 18,439 56,935 28,304 172,478 EBITDA adjustments from continuin
Slide 9: Non-GAAP Reconciliation: Adjusted Operating Cost Ratio
Non-GAAP Reconciliation: Adjusted Operating Cost Ratio Three Months Ended Six Months Ended June 30, June 30, June 30, June 30, ($ in thousands) 2024 2023 2024 2023 GAAP Operating Cost Ratio 31.1% 23.6% 29.1% 25.0% Impact of share-based (9.4)% (5.3)% (8.5)% (8.2)% compensation expense Impact of held-
Slide 10: Forward-Looking Non-GAAP Measures
Forward-Looking Non-GAAP Measures This presentation contains Adjusted EBITDA and Adjusted Operating Cost Ratio, which are non-GAAP financial measures. These non-GAAP financial measures are additions, and not substitutes for or superior to the most directly comparable GAAP financial measures, Net Inc
Slide 11: Slide 11